Lamivudine/tenofovir
 |
| Combination of | |
|---|---|
| Lamivudine | Nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleotide reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Cimduo, Temixys |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a618039 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo among others, is a fixed-dose combination drug for the treatment of HIV/AIDS in adults and children weighing more than 35 kilograms (77 lb).[1] It contains lamivudine and tenofovir disoproxil.[1] In the United States, it was approved by the Food and Drug Administration (FDA) in February 2018, for the treatment of HIV-1 infection.[1][2] It is taken by mouth.[1]
References
- ^ a b c d "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Retrieved 26 March 2020.
- ^ "Drug Approval Package: Cimduo (lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 27 November 2018. Retrieved 26 March 2020.
Further reading
- "WHO Public Assessment Report: HA414 - Lamivudine/Tenofovir disoproxil fumarate - 300mg/300mg - Tablets - Mylan Laboratories Ltd - India". World Health Organization (WHO).
External links
- "Lamivudine". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |